A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Exclusion Criteria

• •Metastatic disease (Stage IV) or bilateral breast cancer
• •Participants who have had an incisional biopsy of the primary tumor or the primary tumor excised
• •Prior breast or non-breast malignancy within 5 years prior to study entry, except for carcinoma in situ and basal cell and squamous cell carcinoma of the skin. Participants with malignancies occurring more than 5 years prior to study entry are permitted if curatively treated
• •Any previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancer
• •Participants with a past history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) are not allowed to enter the study if they have received any systemic therapy for its treatment or radiation therapy to the ipsilateral breast (they are allowed to enter the study if treated with surgery alone)
• •High-risk participants who have received chemopreventive drugs in the past are not allowed to enter the study
• •Inadequate bone marrow, renal, or liver function
• •History or evidence of cardiovascular condition
• •Dyspnea at rest or other diseases that require continuous oxygen therapy
• •Severe, uncontrolled systemic disease
• •Participants with poorly controlled diabetes or with evidence of clinically significant diabetic vascular complications
• •Pregnancy or breast-feeding women
• •Participants who received any investigational treatment within 4 weeks of study start
• •Participants with known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
• •Current chronic daily treatment with corticosteroids (dose \>10 mg methylprednisolone or equivalent \[excluding inhaled steroids\])
• •Known hypersensitivity to any of the study drugs or excipients